Printer Friendly

Helomics, UPMC collaborate to establish AI-approach to ovarian cancer treatment.

Predictive Oncology subsidiary Helomics announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. Helomics is a subsidiary of Predictive Oncology Inc., a company focused on applying artificial intelligence to personalized medicine and drug discovery. The collaboration will focus on using Helomics' artificial intelligence platform to analyze the genomic and drug response profiles of women with ovarian cancer to determine predictive value in terms of response/non-response to therapy. The parties believe that the collaboration will demonstrate the value of using AI-powered, evidence-based decision making, in the context of specific treatments on specific genotypes, to predict clinical outcomes for this group of patients. Work performed under the collaboration will be funded in part by UPMC Enterprises. UPMC Enterprises, the commercialization and innovation arm of UPMC, was established to generate and enable exceptional health care innovations focusing on two main areas: translational science and digital health solutions.

COPYRIGHT 2019 The Fly
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:The Fly
Date:Jul 18, 2019
Previous Article:Saltstone Capital sends letter to board of Abraxas Petroleum.
Next Article:Jefferies downgrades Trade Desk to Hold after five-fold rally since early 2018.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters